PharmaDiagnostics appoints director of assay development

Former pharma department head joins Belgian firm

PharmaDiagnostics, a developer of label-free screening technology that does not require specialised instrumentation, has appointed Dr Sylviane Boucharens as director of assay development. She joins from Merck’s MSD site in Newhouse, Scotland, where she was head of global compound repository and in vitro screening.

Boucharens will play a central role in driving the growth of PharmaDiagnostics’ assay product range, and in developing business globally. She worked at Merck from 2000 to 2011. She started her career in the pharmaceutical industry in 1995 when she joined the Immunology Department in the Laboratoires Fournier (Dijon, France).

You may also like

Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Manufacturing

Transforming healthcare with patient centricity

In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact they’re having on the pharmaceutical industry
Manufacturing

Medincell collaborates with AbbVie to develop next-generation long-acting injectable therapies

The partnership will focus on the development and commercialisation of six long-acting injectable therapies across various therapeutic areas
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Manufacturing

ISPE announces 2024 Facility of the Year Awards category winners

The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Manufacturing

ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector

The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Subscribe now